New PET scan agent could predict cancer therapy success, but trial never started
Diagnosis
Terminated
This pilot study aimed to test whether a radioactive imaging agent called 68Ga-FAPI-46 could predict how well solid tumor patients respond to antibody therapy. The plan was to give 50 participants an injection of the agent, then perform a PET/CT scan and compare it to standard MR…
Phase: EARLY_PHASE1 • Sponsor: Eben Rosenthal • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC